Ascentage Pharma Group International (NASDAQ:AAPG) Sees Unusually-High Trading Volume – Should You Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw unusually-high trading volume on Wednesday . Approximately 3,028 shares were traded during trading, a decline of 7% from the previous session’s volume of 3,243 shares.The stock last traded at $26.16 and had previously closed at $23.87.

Wall Street Analyst Weigh In

AAPG has been the subject of a number of analyst reports. Rodman & Renshaw began coverage on Ascentage Pharma Group International in a research report on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price target for the company. BTIG Research reaffirmed a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research report on Thursday, March 26th. Oppenheimer started coverage on Ascentage Pharma Group International in a research note on Thursday, December 4th. They set an “outperform” rating and a $45.00 price objective for the company. Finally, Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $48.00.

Ascentage Pharma Group International Stock Up 4.3%

The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57. The firm’s fifty day moving average is $23.92 and its two-hundred day moving average is $29.46.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The business had revenue of $24.72 million during the quarter.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. bought a new position in Ascentage Pharma Group International in the 3rd quarter worth approximately $96,000. ABC Arbitrage SA purchased a new position in shares of Ascentage Pharma Group International in the third quarter worth $204,000. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International in the third quarter worth $383,000. Hsbc Holdings PLC bought a new position in shares of Ascentage Pharma Group International during the second quarter worth $391,000. Finally, Tema Etfs LLC purchased a new position in Ascentage Pharma Group International during the second quarter valued at $610,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.